Welcome to Paid Research Studies




  • Condition:   Secondary Immune Deficiency Disorder
    Intervention:   Drug: Hizentra
    Sponsor:   Rochester General Hospital
    Recruiting

  • Conditions:   IgG4-related Sclerosing Cholangitis;   IgG4-related Disease
    Intervention:  
    Sponsors:   Mayo Clinic;   Nagoya University
    Recruiting

  • Conditions:   Epithelial Neoplasms, Malignant;   Epithelial Tumors, Malignant;   Malignant Mesenchymal Tumor
    Intervention:   Drug: NHS-IL-12
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Human Papillomavirus Infection;   Stage I Oral Cavity Squamous Cell Carcinoma;   Stage I Oropharyngeal Squamous Cell Carcinoma;   Stage II Oral Cavity Squamous Cell Carcinoma;   Stage II Oropharyngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non Small Cell Lung Cancer
    Intervention:   Drug: durvalumab
    Sponsor:   Liza Villaruz, MD
    Recruiting

  • Conditions:   Maternal Syphilis During Pregnancy - Baby Not Yet Delivered;   Congenital Syphilis
    Intervention:   Diagnostic Test: Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
    Sponsors:   Stanford University;   Santa Clara Valley Medical Center
    Not yet recruiting

  • Conditions:   Chordoma;   Locally Advanced Chordoma;   Metastatic Chordoma;   Unresectable Chordoma
    Interventions:   Biological: Nivolumab;   Biological: Relatlimab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Peripheral T Cell Lymphoma
    Interventions:   Drug: Nivolumab;   Drug: cabiralizumab
    Sponsors:   Big Ten Cancer Research Consortium;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Hemophilia
    Intervention:   Drug: BAY1093884
    Sponsor:   Bayer
    Not yet recruiting

  • Conditions:   Triple -Negative Breast Cancer;   Estrogen Receptor Negative;   HER2/Neu Negative;   Anatomic Stage IV Breast Cancer AJCC;   Progesterone Receptor Negative
    Interventions:   Procedure: Biopsy;   Procedure: Chemokine Modulation Therapy;   Drug: Celecoxib;   Biological: Recombinant Interferon Alfa-2b;   Drug: Rintatolimod;   Biological: Pembrolizumab
    Sponsor:   Roswell Park Cancer Institute
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Talazoparib;   Drug: Avelumab
    Sponsors:   Georgetown University;   Pfizer
    Recruiting

  • Condition:   Gliomas
    Intervention:   Drug: Nivolumab
    Sponsors:   Fabio Iwamoto, MD;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Advanced Melanoma;   Non-small Cell Lung Cancer;   Renal Cell Carcinoma
    Interventions:   Drug: APX005M;   Drug: Cabiralizumab;   Drug: Nivolumab
    Sponsors:   Yale University;   Bristol-Myers Squibb;   Apexigen, Inc.
    Recruiting

  • Conditions:   Oncology;   Solid Tumor;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Melanoma;   Bladder Cancer
    Interventions:   Drug: MRx0518;   Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
    Sponsors:   4D pharma plc;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Hydronephrosis;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant;   Renal Pelvis Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage II Renal Pelvis Cancer AJCC v7;   Stage II Ureter Cancer AJCC v7;   Stage II Urethral Cancer AJCC v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
    Interventions:   Biological: Durvalumab;   Procedure: Therapeutic Conventional Surgery;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Durvalumab;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Carcinoma in the Liver;   Resectable Mass;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Drug: Anti-AXL Fusion Protein AVB-S6-500;   Biological: Durvalumab
    Sponsors:   M.D. Anderson Cancer Center;   Aravive, Inc.;   AstraZeneca;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Human Papillomavirus-16 Positive;   Human Papillomavirus-18 Positive;   Metastatic Malignant Neoplasm;   Recurrent Anal Canal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Penile Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Refractory Malignant Neoplasm;   Stage IV Anal Cancer AJCC v8;   Stage IV Cervical Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Vaginal Cancer AJCC v8;   Stage IV Vulvar Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8;   Stage IVA Vulvar Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Vaginal Cancer AJCC v8;   Stage IVB Vulvar Cancer AJCC v8
    Interventions:   Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457;   Biological: Durvalumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Ovarian Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Biological: Tremelimumab
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cutaneous Melanoma;   Mucosal Melanoma;   Ocular Melanoma;   Stage III Acral Lentiginous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIB Uveal Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IIIC Uveal Melanoma AJCC v7;   Stage IV Acral Lentiginous Melanoma AJCC v6 and v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IV Uveal Melanoma AJCC v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Relatlimab;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma
    Interventions:   Biological: Fresolimumab;   Other: Pharmacological Study;   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   Maximilian Diehn;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Folliculotropic Mycosis Fungoides;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Sezary Syndrome;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hodgkin's Lymphoma
    Interventions:   Biological: Pembrolizumab;   Drug: Umbralisib
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Ficlatuzumab
    Sponsors:   Dana-Farber Cancer Institute;   AVEO Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Stage IV
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Radiation: Stereotactic Body Radiotherapy
    Sponsors:   University of Wisconsin, Madison;   AstraZeneca;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Head and Neck Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma
    Interventions:   Drug: Metformin;   Biological: Durvalumab
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   HNSCC;   Lip SCC;   Oral Cavity Cancer;   Oropharynx Cancer;   Larynx Cancer;   Hypopharynx Cancer;   Nasopharynx Cancer;   Sinonasal Carcinoma;   Cutaneous Squamous Cell Carcinoma;   Head and Neck Neoplasms;   Head and Neck Cancer;   Head and Neck Squamous Cell Carcinoma
    Intervention:   Drug: Pembrolizumab, Cetuximab
    Sponsors:   Assuntina G. Sacco;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8
    Interventions:   Biological: Durvalumab;   Radiation: External Beam Radiation Therapy;   Biological: Tremelimumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Biological: Durvalumab;   Drug: Selumetinib;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Body Radiation Therapy;   Biological: Tremelimumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Refractory Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Unresectable Lung Non-Small Cell Carcinoma
    Interventions:   Drug: Atezolizumab 1200 MG in 20 ML Injection;   Radiation: Stereotactic Body Radiation Therapy;   Drug: Varlilumab 3 mg/kg
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Human Papillomavirus Positive;   Human Papillomavirus-Related Cervical Squamous Cell Carcinoma;   Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma;   Metastatic Cervical Adenocarcinoma;   Metastatic Cervical Carcinoma;   Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Metastatic Vaginal Adenocarcinoma;   Metastatic Vaginal Carcinoma;   Metastatic Vulvar Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Stage IV Cervical Cancer AJCC v8;   Stage IV Vaginal Cancer AJCC v8;   Stage IV Vulvar Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8;   Stage IVA Vulvar Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Vaginal Cancer AJCC v8;   Stage IVB Vulvar Cancer AJCC v8;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Radiosurgery;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   COL6A3 Positive;   HLA-A*0201 Positive Cells Present;   PRAME Positive;   Recurrent Ovarian Carcinoma
    Interventions:   Biological: Aldesleukin;   Drug: CD8-Positive T-Lymphocyte;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Utomilumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Non-small Cell Lung Cancer;   Metastatic Triple-negative Breast Cancer
    Interventions:   Biological: ADV/HSV-tk;   Drug: Valacyclovir;   Radiation: SBRT;   Drug: Pembrolizumab
    Sponsors:   Jenny C. Chang, MD;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
    Interventions:   Biological: Pembrolizumab;   Biological: pTVG-HP Plasmid DNA Vaccine
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Refractory or Recurrent Hypermutated Malignancies;   Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
    Intervention:   Drug: Nivolumab
    Sponsor:   The Hospital for Sick Children
    Recruiting

  • Conditions:   Prostate Cancer;   Prostate Disease
    Interventions:   Drug: Nivolumab;   Radiation: Brachytherapy;   Radiation: External Beam Radiation Therapy;   Drug: Androgen Deprivation Therapy
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Stage III Fallopian Tube Cancer AJCC v7;   Stage III Ovarian Cancer AJCC v6 and v7;   Stage III Primary Peritoneal Cancer AJCC v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   MYC Gene Rearrangement;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   AstraZeneca;   Juno Therapeutics, Inc.;   MedImmune LLC;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Pain
    Interventions:   Drug: Immune Globulin Intravenous;   Other: Normal saline
    Sponsor:   Albert Einstein College of Medicine
    Recruiting

  • Condition:   Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Intervention:   Biological: IgPro10
    Sponsor:   CSL Behring
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Renal Cell Carcinoma;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer
    Interventions:   Drug: AB154;   Drug: AB122
    Sponsor:   Arcus Biosciences, Inc.
    Recruiting

  • Conditions:   Metastatic Bladder Urothelial Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Unresectable Renal Pelvis Urothelial Carcinoma;   Unresectable Ureter Urothelial Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Biological: Pembrolizumab;   Biological: Autologous Tumor Infiltrating Lymphocytes LN-145;   Biological: Aldesleukin
    Sponsors:   Roswell Park Cancer Institute;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Condition:   Chronic Hepatitis B
    Interventions:   Biological: hepatitis B immune globulin;   Drug: Pegylated interferon alfa
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Spinal Muscular Atrophy;   Spinal Muscular Atrophy Type 3;   Spinal Muscular Atrophy Type 2;   SMA;   Neuromuscular Diseases;   Muscular Atrophy;   Atrophy;   Muscular Atrophy, Spinal;   Neuromuscular Manifestations
    Intervention:   Biological: SRK-015
    Sponsor:   Scholar Rock, Inc.
    Recruiting

  • Conditions:   Cervical Adenosarcoma;   Cervical Adenosquamous Carcinoma;   Cervical Carcinosarcoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Mucinous Adenocarcinoma;   Endometrial Squamous Cell Carcinoma;   Endometrial Transitional Cell Carcinoma;   Endometrial Undifferentiated Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Epithelial Tumor;   Malignant Peritoneal Neoplasm;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Skin Melanoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma;   Uterine Corpus Carcinosarcoma
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Appendix Adenocarcinoma;   Human Papillomavirus-Related Anal Squamous Cell Carcinoma;   Human Papillomavirus-Related Cervical Squamous Cell Carcinoma;   Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis;   Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma;   Neuroendocrine Carcinoma;   Pancreatic Neuroendocrine Tumor;   Recurrent Merkel Cell Carcinoma;   Recurrent Nasopharynx Carcinoma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Merkel Cell Carcinoma AJCC v7;   Stage III Nasopharyngeal Carcinoma AJCC v7;   Stage III Pleural Malignant Mesothelioma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7;   Stage IV Nasopharyngeal Carcinoma AJCC v7;   Stage IV Pleural Malignant Mesothelioma AJCC v7;   Stage IVA Nasopharyngeal Carcinoma AJCC v7;   Stage IVB Nasopharyngeal Carcinoma AJCC v7;   Stage IVC Nasopharyngeal Carcinoma AJCC v7;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
    Interventions:   Biological: Cetuximab;   Drug: Irinotecan;   Drug: Irinotecan Hydrochloride;   Other: Pharmacodynamic Study;   Biological: Utomilumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoma;   Myeloma
    Interventions:   Drug: TTI-622 Monotherapy;   Drug: TTI-622 + Rituximab;   Drug: TTI-622 + PD-1 Inhibitor;   Drug: TTI-622 + Proteasome-inhibitor Regimen
    Sponsor:   Trillium Therapeutics Inc.
    Recruiting

  • Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Nivolumab;   Drug: Varlilumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Melanoma
    Interventions:   Biological: DS-8273a;   Biological: Nivolumab
    Sponsors:   NYU Langone Health;   Bristol-Myers Squibb;   Daiichi Sankyo, Inc.
    Recruiting

  • Conditions:   Solid Tumors;   Mycosis Fungoides;   Melanoma;   Merkel-cell Carcinoma;   Squamous Cell Carcinoma;   Breast Carcinoma;   Human Papillomavirus-Related Malignant Neoplasm;   Soft Tissue Sarcoma
    Interventions:   Drug: TTI-621 Monotherapy;   Drug: TTI-621 + PD-1/PD-L1 Inhibitor;   Drug: TTI-621 + pegylated interferon-α2a;   Other: TTI-621 + T-Vec;   Other: TTI-621 + radiation
    Sponsor:   Trillium Therapeutics Inc.
    Recruiting

  • Conditions:   Hematologic Malignancies;   Solid Tumor
    Interventions:   Drug: TTI-621;   Drug: TTI-621 plus Rituximab;   Drug: TTI-621 plus Nivolumab
    Sponsor:   Trillium Therapeutics Inc.
    Recruiting

  • Condition:   Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    Interventions:   Biological: HYQVIA;   Biological: 0.25% albumin placebo solution with rHuPH20;   Biological: IGIV
    Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
    Recruiting

  • Conditions:   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Human Papillomavirus Positive;   Oropharyngeal Squamous Cell Carcinoma;   p16 Positive Neoplastic Cells Present;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Biological: Durvalumab;   Procedure: Modified Radical Neck Dissection;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Radiation Therapy;   Procedure: Transoral Robotic Surgery;   Biological: Tremelimumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Antibody-mediated Rejection
    Interventions:   Biological: Clazakizumab;   Drug: Normal saline
    Sponsors:   Vitaeris INC;   ICON Clinical Research
    Recruiting

  • Conditions:   CD19 Positive;   CD20 Positive;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Tocilizumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   Parker Institute for Cancer Immunotherapy
    Not yet recruiting

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Interventions:   Drug: INCB001158;   Biological: Daratumumab SC
    Sponsor:   Incyte Corporation
    Not yet recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer;   Renal Cell Carcinoma;   Castration-resistant Prostate Cancer
    Interventions:   Drug: AB928;   Drug: AB122
    Sponsor:   Arcus Biosciences, Inc.
    Recruiting

  • Condition:   Atopic Dermatitis
    Interventions:   Drug: Tralokinumab;   Drug: Placebos
    Sponsor:   LEO Pharma
    Recruiting

  • Condition:   Advanced Solid Malignancies
    Interventions:   Biological: MEDI4736 (Durvalumab);   Biological: MEDI4736 (Durvalumab) + Tremelimumab
    Sponsor:   AstraZeneca
    Recruiting

  • Condition:   Other Skin
    Interventions:   Biological: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR;   Drug: Avelumab;   Radiation: Radiation Therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Bluebird Biosciences
    Recruiting

  • Conditions:   Microsatellite Stable;   Mismatch Repair Protein Proficient;   Stage III Colorectal Cancer AJCC v7;   Stage IIIB Colorectal Cancer AJCC v7;   Stage IIIC Colorectal Cancer AJCC v7;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Biological: Bevacizumab;   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   University of California, San Francisco;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Recurrent Brain Neoplasm
    Interventions:   Biological: Bevacizumab;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Triple-Negative Breast Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Biological: Tremelimumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Metastatic Merkel Cell Carcinoma
    Intervention:   Drug: INCMGA00012
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Locally Advanced Malignant Solid Neoplasm;   Metastatic Malignant Solid Neoplasm;   Progressive Disease
    Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Biological: Durvalumab;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lung Non-Small Cell Carcinoma;   PD-L1 Overexpression;   Recurrent Lung Carcinoma;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Biological: Durvalumab;   Radiation: Fractionated Stereotactic Radiation Therapy;   Radiation: Hypofractionated Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Biological: Mogamulizumab;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   GlaxoSmithKline
    Recruiting

  • Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Anetumab Ravtansine;   Biological: Bevacizumab;   Drug: Paclitaxel
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Post-polio Syndrome
    Interventions:   Biological: Flebogamma 5% DIF;   Other: Placebo
    Sponsors:   Grifols Therapeutics LLC;   Instituto Grifols, S.A.
    Recruiting

  • Conditions:   Neuromyelitis Optica;   Devic's Disease;   NMO Spectrum Disorder
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: G-CSF;   Biological: IVIg;   Biological: Autologous Stem Cells
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Squamous Cell Carcinoma of Unknown Primary;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Biological: Cetuximab;   Biological: Durvalumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group;   NRG Oncology
    Recruiting

  • Conditions:   Non Small Cell Lung Cancer Metastatic;   Non Small Cell Lung Cancer;   Nonsquamous Nonsmall Cell Neoplasm of Lung
    Interventions:   Drug: AB928;   Drug: AB122;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Pembrolizumab
    Sponsor:   Arcus Biosciences, Inc.
    Recruiting

  • Condition:   Neoplasms
    Interventions:   Drug: GSK3359609;   Drug: Tremelimumab;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Cetuximab
    Sponsors:   GlaxoSmithKline;   MedImmune LLC
    Recruiting

  • Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Topotecan Hydrochloride
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   EGFR Activating Mutation;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Lung Carcinoma Metastatic in the Brain;   Lung Non-Small Cell Carcinoma
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-small Cell Lung Cancer (NSCLC)
    Intervention:   Drug: Durvalumab
    Sponsor:   AstraZeneca
    Recruiting

  • Conditions:   Clinical Stage 0 Cutaneous Melanoma AJCC v8;   Clinical Stage I Cutaneous Melanoma AJCC v8;   Clinical Stage IA Cutaneous Melanoma AJCC v8;   Clinical Stage IB Cutaneous Melanoma AJCC v8;   Clinical Stage II Cutaneous Melanoma AJCC v8;   Clinical Stage IIA Cutaneous Melanoma AJCC v8;   Clinical Stage IIB Cutaneous Melanoma AJCC v8;   Clinical Stage IIC Cutaneous Melanoma AJCC v8;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Colitis;   Diarrhea;   Malignant Genitourinary System Neoplasm;   Pathologic Stage 0 Cutaneous Melanoma AJCC v8;   Pathologic Stage I Cutaneous Melanoma AJCC v8;   Pathologic Stage IA Cutaneous Melanoma AJCC v8;   Pathologic Stage IB Cutaneous Melanoma AJCC v8;   Pathologic Stage II Cutaneous Melanoma AJCC v8;   Pathologic Stage IIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIC Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Other: Best Practice;   Other: Biospecimen Collection;   Procedure: Endoscopic Procedure;   Procedure: Fecal Microbiota Transplantation;   Biological: Infliximab;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Vedolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8;   Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8;   Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8;   Thyroid Gland Anaplastic Carcinoma;   Unresectable Thyroid Gland Carcinoma
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Cobimetinib;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Drug: Vemurafenib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anaplastic (Malignant) Meningioma;   Atypical Meningioma;   Grade II Meningioma;   Grade III Meningioma;   Recurrent Meningioma;   Supratentorial Meningioma
    Interventions:   Biological: Bevacizumab;   Procedure: Electric Field Therapy;   Device: NovoTTF-200A Device;   Procedure: Quality-of-Life Assessment
    Sponsors:   Northwestern University;   NovoCure Ltd.;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Atezolizumab;   Drug: Hu5F9-G4
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Mismatch Repair Deficiency;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting